Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck

Sassi, Fabrizia; Cazzaniga, Simone; Tessari, Gianpaolo; Chatenoud, Liliane; Reseghetti, A.; Marchesi, L.; Girolomoni, Giampiero; Naldi, Luigi

doi:10.1111/j.1365-2133.2008.08793.x

Cited by 52 publications

(78 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details regarding the trial design and main clinical results have been published elsewhere [6]. A total of 120 patients with different varieties of vitiligo (focal vs. generalized) were initially screened, and 84 underwent randomization.…”

Section: Methodsmentioning

confidence: 99%

“…In a recently completed randomized clinical trial, up to 42% of patients who were previously unresponsive to conventional treatment modalities attained a 75% or greater reduction of the lesional areas of the face and neck when treated with a 12-week course of excimer laser therapy combined with topical corticosteroids [6]. Because the treatment is time consuming and highly demanding in terms of personal commitment, a predictive model for clinical response may have the obvious advantages of helping to select likely responders and anticipating treatment duration in individual patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models

Cazzaniga

Sassi²,

Mercuri³

et al. 2009

Dermatology

View full text Add to dashboard Cite

Background: A predictive model may help to select likely responders and to anticipate treatment duration in vitiligo. Methods: We aimed to develop a predictive rule based on data from a randomized trial of excimer laser in vitiligo. Information on 325 treated patches was available. The degree of repigmentation was assessed by digital image analysis of UVB-reflected photographs. Since no strong relationship between any single predictive parameter and outcome was initially documented, we relied on artificial neural networks. Results: Using a time-response optimal threshold model, data were divided into 2 groups of responders and nonresponders. A discriminant network was trained in order to detect responders versus nonresponders. A regression network was subsequently used to compute repigmentation time in responders. The neural network discriminator achieved 66.46 ± 5.37% (95% CI) overall accuracy. The mean absolute error of the neural network regressor was 19.5843 ± 2.0930 with a root mean square error of 23.7156 ± 2.2225. Conclusion: Our study offers insight into the difficulty of clinical prediction in vitiligo and presents a way to develop an instrument with which to predict the clinical time response in patients treated by excimer laser.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models

Cazzaniga

Sassi²,

Mercuri³

et al. 2009

Dermatology

View full text Add to dashboard Cite

show abstract

“…They also revealed that combination of betamethasone dipropionate and NB-UVB resulted in the highest repigmentation rate (Lotti et al, 2008). In other study, Sassi and colleagues also showed that combination of excimer laser and topical hydrocortisone was effective in treatment of recalcitrant vitiligo of the face and neck (Sassi, 2008). …”

Section: Place Of Corticosteroids In Treatment Of Vitiligomentioning

confidence: 99%

Role of Corticosteroids in Treatment of Vitiligo

Bagherani¹

2012

State of the Art of Therapeutic Endocrinology

View full text Add to dashboard Cite

“…Two were assessed this using DLQI 49,62 and two 407,424 used Skindex-29; however, we were not able to perform statistical analysis on these data. Percentage of repigmentation > 75%…”

Section: Quality Of Lifementioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck

Abstract: Recalcitrant vitiligo of the face and neck may benefit from the combination of excimer laser phototherapy with topical hydrocortisone 17-butyrate cream.

Cited by 52 publications

References 27 publications

Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models

Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models

Role of Corticosteroids in Treatment of Vitiligo

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About